Cyclotides as drug design scaffolds

Current Opinion in Chemical Biology

Volumn 38, Issue , 2017, Pages 8-16

  Craik, David J ^a   Du, Junqiao ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOTIDE; MOLECULAR SCAFFOLD;

DRUG DESIGN; NONHUMAN; REVIEW; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; HUMAN; SYNTHESIS;

AMINO ACID SEQUENCE; ANIMALS; CYCLOTIDES; DRUG DESIGN; HUMANS;

EID: 85013986653     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2017.01.018     Document Type: Review

References (86)

1. 1 Craik, D.J., Daly, N.L., Bond, T., Waine, C., Plant cyclotides: a unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J Mol Biol 294 (1999), 1327–1336.
2. 2 D.J. Craik (Ed.), Advances in Botanical Research: Plant Cyclotdes, vol. 76. Series Eds.: J.-P. Jacquot, P. Gadal, London Academic Press, 2015.
3. 3 Gruber, C.W., Cemazar, M., Anderson, M.A., Craik, D.J., Insecticidal plant cyclotides and related cystine knot toxins. Toxicon 49 (2007), 561–575.
4. 4 Colgrave, M.L., Kotze, A.C., Huang, Y.H., O'Grady, J., Simonsen, S.M., Craik, D.J., Cyclotides: natural, circular plant peptides that possess significant activity against gastrointestinal nematode parasites of sheep. Biochemistry 47 (2008), 5581–5589.
5. 5 Plan, M.R.R., Saska, I., Cagauan, A.G., Craik, D.J., Backbone cyclised peptides from plants show molluscicidal activity against the rice pest Pomacea canaliculata (golden apple snail). J Agric Food Chem 56 (2008), 5237–5241.
6. 6 Huang, Y.-H., Colgrave, M.L., Daly, N.L., Keleshian, A., Martinac, B., Craik, D.J., The biological activity of the prototypic cyclotide kalata B1 is modulated by the formation of multimeric pores. J Biol Chem 284 (2009), 20699–20707.
7. 7 Gran, L., Sletten, K., Skjeldal, L., Cyclic peptides from Oldenlandia affinis DC. Molecular and biological properties. Chem Biodivers 5 (2008), 2014–2022.
8. 8 Saether, O., Craik, D.J., Campbell, I.D., Sletten, K., Juul, J., Norman, D.G., Elucidation of the primary and three-dimensional structure of the uterotonic polypeptide kalata B1. Biochemistry 34 (1995), 4147–4158.
9. 9 Mulvenna, J.P., Wang, C., Craik, D.J., CyBase: a database of cyclic protein sequence and structure. Nucleic Acids Res 34 (2006), D192–D194.
10. 10 Gruber, C.W., Elliott, A.G., Ireland, D.C., Delprete, P.G., Dessein, S., Göransson, U., Trabi, M., Wang, C.K., Kinghorn, A.B., Robbrecht, E., et al. Distribution and evolution of circular miniproteins in flowering plants. Plant Cell 20 (2008), 2471–2483.
11. 11 Wong, C.T.T., Rowlands, D.K., Wong, C.H., Lo, T.W.C., Nguyen, G.K.T., Li, H.Y., Tam, J.P., Orally active peptidic bradykinin B-1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment. Angew Chem Int Ed Engl 51 (2012), 5620–5624.
12. 12•• Ji, Y., Majumder, S., Millard, M., Borra, R., Bi, T., Elnagar, A.Y., Neamati, N., Shekhtman, A., Camarero, J.A., In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. J Am Chem Soc 135 (2013), 11623–11633 The first report of a grafted cyclotide targeting an intracellular protein- protein interaction.
13. 13 D'Souza, C., Henriques, S.T., Wang, C.K., Cheneval, O., Chan, L.Y., Bokil, N.J., Sweet, M.J., Craik, D.J., Using the MCoTI-II cyclotide scaffold to design a stable cyclic peptide antagonist of SET, a protein overexpressed in human cancer. Biochemistry 55 (2016), 396–405.
14. 14 Craik, D.J., Circling the enemy: cyclic proteins in plant defence. Trends Plant Sci 14 (2009), 328–335.
15. 15 Henriques, S.T., Craik, D.J., Importance of the cell membrane on the mechanism of action of cyclotides. ACS Chem Biol 7 (2012), 626–636.
16. 16• Craik, D.J., Joseph Rudinger memorial lecture: discovery and applications of cyclotides. J Pept Sci 19 (2013), 393–407 A review giving a comprehensive introduction to cyclotides.
17. 17 Craik, D.J., Malik, U., Cyclotide biosynthesis. Curr Opin Chem Biol 17 (2013), 546–554.
18. 18 Burman, R., Gunasekera, S., Stromstedt, A.A., Göransson, U., Chemistry and biology of cyclotides: circular plant peptides outside the box. J Nat Prod 77 (2014), 724–736.
19. 19 Colgrave, M.L., Chapter five—primary structural analysis of cyclotides. Craik, D.J., (eds.) Advances in Botanical Research: Plant Cyclotides, vol. 76, 2015, Academic Press, 113–154 Jacquot J-P, Gadal P (Series Editor).
20. 20 Daly, N.L., Rosengren, K.J., Chapter six—structural studies of cyclotides. Craik, D.J., (eds.) Advances in Botanical Research: Plant Cyclotides, vol. 76, 2015, Academic Press, 155–186 Jacquot J-P, Gadal P (Series Editor).
21. 21 Jackson, M.A., Gilding, E.K., Chapter ten—cyclotides in a biotechnological context: opportunities and challenges. Craik, D.J., (eds.) Advances in Botanical Research: Plant Cyclotides, vol. 76, 2015, Academic Press, 305–333 Jacquot J-P, Gadal P (Series Editor).
22. 22 Li, Y., Bi, T., Camarero, J.A., Chapter nine—chemical and biological production of cyclotides. Craik, D.J., (eds.) Advances in Botanical Research: Plant Cyclotides, vol. 76, 2015, Academic Press, 271–303 Jacquot J-P, Gadal P (Series Editor).
23. 23 Phoenix, D.A., Harris, F., Mura, M., Dennison, S.R., The increasing role of phosphatidylethanolamine as a lipid receptor in the action of host defence peptides. Prog Lipid Res 59 (2015), 26–37.
24. 24• Weidmann, J., Craik, D.J., Discovery, structure, function, and applications of cyclotides: circular proteins from plants. J Exp Bot 67 (2016), 4801–4812 The most recent review giving an overview on the discovery and applications of cyclotides.
25. 25 Craik, D.J., Cĕmažar, M., Daly, N.L., The cyclotides and related macrocyclic peptides as scaffolds in drug design. Curr Opin Drug Discov Dev 9 (2006), 251–260.
26. 26 Craik, D.J., Cĕmažar, M., Wang, C.K., Daly, N.L., The cyclotide family of circular miniproteins: nature's combinatorial peptide template. Biopolymers: Pept Sci 84 (2006), 250–266.
27. 27 Craik, D.J., Clark, R.J., Daly, N.L., Potential therapeutic applications of the cyclotides and related cystine knot mini-proteins. Expert Opin Investig Drugs 16 (2007), 595–604.
28. 28 Kolmar, H., Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins. FEBS J 275 (2008), 2684–2690.
29. 29 Daly, N.L., Craik, D.J., Design and therapeutic applications of cyclotides. Future Med Chem 1 (2009), 1613–1622.
30. 30 Craik, D.J., Mylne, J.S., Daly, N.L., Cyclotides: macrocyclic peptides with applications in drug design and agriculture. Cell Mol Life Sci 67 (2010), 9–16.
31. 31 Jagadish, K., Camarero, J.A., Cyclotides, a promising molecular scaffold for peptide-based therapeutics. Biopolymers: Pept Sci 94 (2010), 611–616.
32. 32 Daly, N.L., Craik, D.J., Bioactive cystine knot proteins. Curr Opin Chem Biol 15 (2011), 362–368.
33. 33 Gracy, J., Chiche, L., Structure and modeling of knottins, a promising molecular scaffold for drug discovery. Curr Pharm Des 17 (2011), 4337–4350.
34. 34 Smith, A.B., Daly, N.L., Craik, D.J., Cyclotides: a patent review. Expert Opin Ther Pat 21 (2011), 1657–1672.
35. 35 Craik, D.J., Swedberg, J.E., Mylne, J.S., Čemažar, M., Cyclotides as a basis for drug design. Expert Opin Drug Discov 7 (2012), 179–194.
36. 36 Poth, A.G., Chan, L.Y., Craik, D.J., Cyclotides as grafting frameworks for protein engineering and drug design applications. Biopolymers: Pept Sci 100 (2013), 480–491.
37. 37 Schroeder, C.I., Swedberg, J.E., Craik, D.J., Recent progress towards pharmaceutical applications of disulfide-rich cyclic peptides. Curr Protein Pept Sci 14 (2013), 532–542.
38. 38 Ackerman, S.E., Currier, N.V., Bergen, J.M., Cochran, J.R., Cystine-knot peptides: emerging tools for cancer imaging and therapy. Expert Rev Proteomics 11 (2014), 561–572.
39. 39 Thell, K., Hellinger, R., Schabbauer, G., Gruber, C.W., Immunosuppressive peptides and their therapeutic applications. Drug Discov Today 19 (2014), 645–653.
40. 40 Mollica, A., Costante, R., Stefanucci, A., Novellino, E., Cyclotides: a natural combinatorial peptide library or a bioactive sequence player?. J Enzyme Inhib Med Chem 30 (2015), 575–580.
41. 41 Dawson, P.E., Muir, T.W., Clark-Lewis, I., Kent, S.B., Synthesis of proteins by native chemical ligation. Science 266 (1994), 776–779.
42. 42• Aboye, T., Kuang, Y., Neamati, N., Camarero, J.A., Rapid parallel synthesis of bioactive folded cyclotides by using a tea-bag approach. ChemBioChem 16 (2015), 827–833 Paper reporting rapid parallel synthesis of a small library of bioactive cyclotides.
43. 43 Akcan, M., Craik, D.J., Synthesis of cyclic disulfide-rich peptides. Jensen, K.J., Tofteng Shelton, P., Pedersen, S.L., (eds.) Peptide Synthesis and Applications, 2013, Humana Press, 89–101 Methods in Molecular Biology, vol. 1047.
44. 44 Gunasekera, S., Daly, N., Clark, R., Craik, D.J., Dissecting the oxidative folding of circular cystine knot miniproteins: Development of hybrid cyclotide scaffolds for protein engineering. Antioxid Redox Signal 11 (2009), 971–980.
45. 45 Aboye, T.L., Clark, R.J., Burman, R., Roig, M.B., Craik, D.J., Goransson, U., Interlocking disulfides in circular proteins: toward efficient oxidative folding of cyclotides. Antioxid Redox Signal 14 (2011), 77–86.
46. 46 Cheneval, O., Schroeder, C.I., Durek, T., Walsh, P., Huang, Y.-H., Liras, S., Price, D.A., Craik, D.J., Fmoc-based synthesis of disulfide-rich cyclic peptides. J Org Chem 79 (2014), 5538–5544.
47. 47 Aboye, T.L., Camarero, J.A., Biological synthesis of circular polypeptides. J Biol Chem 287 (2012), 27026–27032.
48. 48•• Nguyen, G.K.T., Wang, S.J., Qiu, Y.B., Hemu, X., Lian, Y.L., Tam, J.P., Butelase 1 is an Asx-specific ligase enabling peptide macrocyclization and synthesis. Nat Chem Biol 10 (2014), 732–738 Paper reporting the isolation of the enzyme butelase-1 with broad utility for cyclising peptides.
49. 49•• Harris, K.S., Durek, T., Kaas, Q., Poth, A.G., Gilding, E.K., Conlan, B.F., Saska, I., Daly, N.L., van der Weerden, N.L., Craik, D.J., et al. Efficient backbone cyclization of linear peptides by a recombinant asparaginyl endopeptidase. Nat Commun, 6, 2015, 10199 Paper reporting the recombinant production of the enzyme OaAEP1b with broad utility for cyclising peptides.
50. 50 Clark, R.J., Daly, N.L., Craik, D.J., Structural plasticity of the cyclic-cystine-knot framework: implications for biological activity and drug design. Biochem J 394 (2006), 85–93.
51. 51 Gunasekera, S., Foley, F.M., Clark, R.J., Sando, L., Fabri, L.J., Craik, D.J., Daly, N.L., Engineering stabilized vascular endothelial growth factor-A antagonists: synthesis, structural characterization, and bioactivity of grafted analogues of cyclotides. J Med Chem 51 (2008), 7697–7704.
52. 52 Thongyoo, P., Roque-Rosell, N., Leatherbarrow, R.J., Tate, E.W., Chemical and biomimetic total syntheses of natural and engineered MCoTI cyclotides. Org Biomol Chem 6 (2008), 1462–1470.
53. 53 Thongyoo, P., Bonomelli, C., Leatherbarrow, R.J., Tate, E.W., Potent inhibitors of β-tryptase and human leukocyte elastase based on the MCoTI-II scaffold. J Med Chem 52 (2009), 6197–6200.
54. 54 Gao, Y., Cui, T., Lam, Y., Synthesis and disulfide bond connectivity-activity studies of a kalata B1-inspired cyclopeptide against dengue NS2B-NS3 protease. Bioorg Med Chem 18 (2010), 1331–1336.
55. 55 Sommerhoff, C.P., Avrutina, O., Schmoldt, H.U., Gabrijelcic-Geiger, D., Diederichsen, U., Kolmar, H., Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase β. J Mol Biol 395 (2010), 167–175.
56. 56 Chan, L.Y., Gunasekera, S., Henriques, S.T., Worth, N.F., Le, S.J., Clark, R.J., Campbell, J.H., Craik, D.J., Daly, N.L., Engineering pro-angiogenic peptides using stable disulfide-rich cyclic scaffolds. Blood 118 (2011), 6709–6717.
57. 57 Aboye, T.L., Ha, H., Majumder, S., Christ, F., Debyser, Z., Shekhtman, A., Neamati, N., Camarero, J.A., Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. J Med Chem 55 (2012), 10729–10734.
58. 58 Eliasen, R., Daly, N.L., Wulff, B.S., Andresen, T.L., Conde-Frieboes, K.W., Craik, D.J., Design, synthesis, structural and functional characterization of novel melanocortin agonists based on the cyclotide kalata B1. J Biol Chem 287 (2012), 40493–40501.
59. 59 Getz, J.A., Cheneval, O., Craik, D.J., Daugherty, P.S., Design of a cyclotide antagonist of neuropilin-1 and -2 that potently inhibits endothelial cell migration. ACS Chem Biol 8 (2013), 1147–1154.
60. 60 Quimbar, P., Malik, U., Sommerhoff, C.P., Kaas, Q., Chan, L.Y., Huang, Y.-H., Grundhuber, M., Dunse, K., Craik, D.J., Anderson, M.A., et al. High-affinity cyclic peptide matriptase inhibitors. J Biol Chem 288 (2013), 13885–13896.
61. 61 Wang, C.K., Gruber, C.W., Cěmažar, M., Siatskas, C., Tagore, P., Payne, N., Sun, G., Wang, S., Bernard, C.C., Craik, D.J., Molecular grafting onto a stable framework yields novel cyclic peptides for the treatment of multiple sclerosis. ACS Chem Biol 9 (2014), 156–163.
62. 62 Chan Lai, Y., Craik David, J., Daly Norelle, L., Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration. Biosci Rep, 35, 2015, e00270.
63. 63 Huang, Y.-H., Henriques, S.T., Wang, C.K., Thorstholm, L., Daly, N.L., Kaas, Q., Craik, D.J., Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold. Sci Rep, 5, 2015, 12974.
64. 64• Jagadish, K., Gould, A., Borra, R., Majumder, S., Mushtaq, Z., Shekhtman, A., Camarero, J.A., Recombinant expression and phenotypic screening of a bioactive cyclotide against α-synuclein-induced cytotoxicity in baker's yeast. Angew Chem Int Ed 54 (2015), 8390–8394 The first paper to report the recombinant expression of cyclotides inside live yeast cells.
65. 65 Maaß, F., Wustehube-Lausch, J., Dickgiessr, S., Valldorf, B., Reinwarth, M., Schmoldt, H.U., Daneschdar, M., Avrutina, O., Sahin, U., Kolmar, H., Cystine-knot peptides targeting cancer-relevant human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Pept Sci 21 (2015), 651–660.
66. 66 Sangphukieo, A., Nawae, W., Laomettachit, T., Supasitthimethee, U., Ruengjitchatchawalya, M., Computational design of hypothetical new peptides based on a cyclotide scaffold as HIV gp120 inhibitor. PLoS One, 10, 2015, e0139562.
67. 67 Aboye, T., Meeks, C., Majumder, S., Shekhtman, A., Rodgers, K., Camarero, J., Design of a MCoTI-based cyclotide with angiotensin (1-7)-like activity. Molecules, 21, 2016, 152.
68. 68•• Chan, L.Y., Craik, D.J., Daly, N.L., Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy. Sci Rep, 6, 2016, 35347 An example of dual grafting of a cyclotide scaffold- in this case by grafting two anti-angiogenic epitopes targeting cancer.
69. 69 Conibear, A.C., Chaousis, S., Durek, T., Rosengren, K.J., Craik, D.J., Schroeder, C.I., Approaches to the stabilization of bioactive epitopes by grafting and peptide cyclization. Biopolymers: Pept Sci 106 (2016), 89–100.
70. 70 Swedberg, J.E., Mahatmanto, T., Abdul Ghani, H., de Veer, S.J., Schroeder, C.I., Harris, J.M., Craik, D.J., Substrate-guided design of selective FXIIa inhibitors based on the plant-derived Momordica cochinchinensis trypsin inhibitor-II (MCoTI-II) scaffold. J Med Chem 59 (2016), 7287–7292.
71. 71• Thell, K., Hellinger, R., Sahin, E., Michenthaler, P., Gold-Binder, M., Haider, T., Kuttke, M., Liutkevičiūtė, Z., Göransson, U., Gründemann, C., et al. Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis. Proc Natl Acad Sci U S A 113 (2016), 3960–3965 A paper reporting oral activity for a cyclotide active in an animal model of multiple sclerosis.
72. 72 Kimura, R.H., Tran, A.-T., Camarero, J.A., Biosynthesis of the cyclotide kalata B1 by using protein splicing. Angew Chem Int Ed 118 (2006), 987–990.
73. 73 Werle, M., Schmitz, T., Haung, H.-L., Wentzel, A., Kolmar, H., Bernkop-Schnurch, A., The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in organ peptide drug delivery. J Drug Target 14 (2006), 137–146.
74. 74 Aboye, T.L., Clark, R.J., Craik, D.J., Göransson, U., Ultra stable peptide scaffolds for protein engineering—synthesis and folding of the circular cystine knotted cyclotide cycloviolacin O2. ChemBioChem 9 (2008), 103–113.
75. 75 Avrutina, O., Schmoldt, H.U., Gabrijelcic-Geiger, D., Wentzel, A., Frauendorf, H., Sommerhoff, C.P., Diederichsen, U., Kolmar, H., Head-to-tail cyclized cystine-knot peptides by a combined recombinant and chemical route of synthesis. ChemBioChem 9 (2008), 33–37.
76. 76 Austin, J., Wang, W., Puttamadappa, S., Shekhtman, A., Camarero, J.A., Biosynthesis and biological screening of a genetically encoded library based on the cyclotide MCoTI-I. ChemBioChem 10 (2009), 2663–2670.
77. 77 Getz, J.A., Rice, J.J., Daugherty, P.S., Protease-resistant peptide ligands from a knottin scaffold library. ACS Chem Biol 6 (2011), 837–844.
78. 78 Glotzbach, B., Reinwarth, M., Weber, N., Fabritz, S., Tomaszowski, M., Fittler, H., Christmann, A., Avrutina, O., Kolmar, H., Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1. PLoS One, 8, 2013, e76956.
79. 79• Jagadish, K., Borra, R., Lacey, V., Majumder, S., Shekhtman, A., Wang, L., Camarero, J.A., Expression of fluorescent cyclotides using protein trans-splicing for easy monitoring of cyclotide–protein interactions. Angew Chem Int Ed 52 (2013), 3126–3131 This paper showed that cyclotides containing the non-natural amino acid AziF can be labeled to monitor cyclotide-protein interactions.
80. 80 Koehbach, J., O'Brien, M., Muttenthaler, M., Miazzo, M., Akcan, M., Elliott, A.G., Daly, N.L., Harvey, P.J., Arrowsmith, S., Gunasekera, S., et al. Oxytocic plant cyclotides as templates for peptide G protein-coupled receptor ligand design. Proc Natl Acad Sci U S A 110 (2013), 21183–21188.
81. 81 Gray, K., Elghadban, S., Thongyoo, P., Owen, K.A., Szabo, R., Bugge, T.H., Tate, E.W., Leatherbarrow, R.J., Ellis, V., Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II. Thromb Haemost 112 (2014), 402–411.
82. 82 Senthilkumar, B., Kumar, P., Rajasekaran, R., In-silico template selection of in-vitro evolved kalata B1 of Oldenlandia affinis for scaffolding peptide-based drug design. J Cell Biochem 117 (2016), 66–73.
83. 83 Huang, Y.H., Colgrave, M.L., Clark, R.J., Kotze, A.C., Craik, D.J., Lysine-scanning mutagenesis reveals a previously unidentified amendable face of the cyclotide kalata B1 for the optimisation of nematocidal activity. J Biol Chem 285 (2010), 10797–10805.
84. 84• Craik, D.J., Fairlie, D.P., Liras, S., Price, D., The future of peptide-based drugs. Chem Biol Drug Des 81 (2013), 136–147 A recent review on the potential of peptides, including cyclotides, in drug development.
85. 85 Wang, C.K., Colgrave, M.L., Ireland, D.C., Kaas, Q., Craik, D.J., Despite a conserved cystine knot motif, different cyclotides have different membrane binding modes. Biophys J 97 (2009), 1471–1481.
86. 86 Burman, R., Stromstedt, A.A., Malmsten, M., Göransson, U., Cyclotide-membrane interactions: defining factors of membrane binding, depletion and disruption. Biochim Biophys Acta Biomembr 1808 (2011), 2665–2673.